NVST

Envista Holdings Corporation

$24.49

-0.69%
Nov 13, 2026
Bobby Quantitative Model
Envista Holdings Corporation is a global dental products company that develops, manufactures, and markets a portfolio of dental consumables, equipment, and services to dental professionals across two reporting segments: Specialty Products & Technologies (dental implants, regenerative solutions, prosthetics, orthodontic brackets and aligners) and Equipment & Consumables (imaging systems, instruments, and infection prevention). Spun off from Danaher in 2019, Envista is positioned as a broad-line dental platform with a premium implant franchise (Nobel Biocare) and an orthodontics business (Ormco), competing against larger diversified medtech players and specialized implant rivals in a fragmented, clinician-driven market. The current investor narrative centers on a sharp profitability inflection — Q3 2026 net income of $508.3M and EPS of $3.16 were inflated by a large one-time gain (other non-cash items of -$402.9M in the cash flow statement), so the debate is whether underlying margin recovery and modest revenue growth (+3.2% YoY) are durable or optically flattered. Sentiment is also shaped by soft dental demand commentary across the space (as reflected in peer XRAY's margin pressure), a recent Baird downgrade to Neutral, and a stock that has outperformed the market over the past year despite a choppy three-month stretch.

People also watch

Intuitive Surgical

Intuitive Surgical

ISRG

Analysis
Becton Dickinson

Becton Dickinson

BDX

Analysis
ResMed

ResMed

RMD

Analysis
Modernland Realty Ltd

Modernland Realty Ltd

MDLN

Analysis
West Pharmaceutical Services (United States)

West Pharmaceutical Services (United States)

WST

Analysis

BobbyInvestment Opinion: Should I buy NVST Today?

Rating: Hold. Envista is a low-multiple, cash-generative dental franchise whose stock already reflects most of the near-term recovery case, and with only 3 analysts covering it, a split ratings panel (Evercore ISI and Leerink at Outperform, JP Morgan upgraded to Overweight, but UBS, Piper Sandler, BMO and Needham at Neutral/Hold, and Baird downgraded to Neutral in mid-October) and no published consensus price target, there is no anchor for meaningful upside. The core thesis is that a 55%+ gross-margin medtech business trading at 1.34x sales and roughly 12.7x the $1.98 consensus EPS is priced for stagnation, so modest execution on the $3.17B revenue consensus would support a re-rating — but the evidence for that step-up is not yet in hand.

Supporting evidence is mixed but leans toward value support rather than momentum. Valuation is undemanding at 1.34x PS, 1.17x P/B and 12.2x EV/EBITDA, versus historical PS of 5.5x-6.1x in 2022-2023 and 8.3x-13.7x in 2022, placing the stock near the bottom of its own multi-year band. Gross margin has held at 55.0%-57.9% across the last four quarters (Q3 2026: 57.9%), and the balance sheet is solid with $1.159B of cash, a 2.38 current ratio and 0.51 debt-to-equity. But revenue grew only 3.22% YoY in Q3 2026 ($691.5M vs. $669.9M), the trailing four-quarter run-rate is roughly $2.88B against a $3.17B consensus that implies about 10% growth, TTM free cash flow of $226.2M is a modest ~6.2% yield on the $3.65B market cap, and ROE is just 1.51%. The 29.21% one-year gain versus SPY's 9.59% (19.62 points of relative strength) means much of the easy recovery has already been captured.

Three risks could invalidate the thesis: consensus revenue of $3.17B failing to materialize off the ~$2.88B run-rate, further estimate cuts or downgrades in a thin three-analyst coverage set, and soft dental utilization (as seen in peer XRAY's margin compression) hitting the higher-margin Specialty Products & Technologies segment ($1.208B of revenue). This Hold would upgrade to Buy if revenue growth accelerates above 6-7% YoY with gross margin holding near 58% and the stock still trades below 1.5x sales, or if a credible consensus price target emerges implying 20%+ upside; it would downgrade to Sell on a close below the $22.40 52-week low or a cut to the $1.98 EPS consensus. Net verdict: fairly valued to modestly undervalued relative to its own history, but not yet cheap enough relative to its 3.2% growth to justify a Buy.

Sign up to view all

NVST 12-Month Price Forecast

Envista screens as a cheap, well-capitalized dental franchise whose stock has already re-rated 29.21% over the past year versus SPY's 9.59%, leaving less room for further multiple expansion without fundamental confirmation. The valuation at 1.34x sales and roughly 12.7x the $1.98 consensus EPS is undemanding, and gross margin near 58% plus $1.159B of cash and 0.51 debt-to-equity provide real downside support, but 3.22% revenue growth and a ~6.2% FCF yield do not yet justify a more constructive stance. The Q3 2026 headline EPS of $3.16 was inflated by a one-time gain (other non-cash items of -$402.9M), so the market is correctly focused on normalized earnings power rather than the reported print. I would upgrade to bullish if revenue growth accelerates above 6-7% with gross margin holding near 58% and the stock still trades below 1.5x sales, and downgrade to bearish on a close below the $22.40 52-week low or a cut to the $1.98 EPS consensus.

Historical Price
Current Price $24.49
Average Target $24.49
High Target $28.16
Low Target $20.82

Wall Street consensus

Coverage is thin, with only 3 analysts contributing to the consensus estimate set, and the institutional ratings feed shows a decidedly mixed stance: Evercore ISI and Leerink Partners at Outperform, JP Morgan upgraded to Overweight in September, but UBS, Piper Sandler, BMO Capital, and Needham at Neutral/Hold, and Baird downgraded from Outperform to Neutral in mid-October. The consensus EPS estimate of $1.98 (range $1.965–$2.017) and revenue estimate of $3.17B (range $3.15B–$3.21B) are tightly clustered, implying analysts broadly agree on the near-term numbers even as their ratings diverge. Against the $25.17 price, the $1.98 EPS estimate implies roughly 12.7x forward earnings, a multiple that leans neutral-to-cautious rather than bullish.

The narrow dispersion in estimates (EPS spread of only about 2.6% from low to high) signals high conviction on the near-term earnings trajectory but low visibility on anything beyond it, and the absence of a published consensus price target in the data means implied upside cannot be calculated directly. The high-end EPS of $2.017 would require modest multiple expansion or better-than-expected implant/ortho demand, while the low end of $1.965 prices in continued soft dental utilization and SG&A deleverage. With only 3 analysts and a recent downgrade trend (Baird cutting to Neutral), price discovery is likely to remain inefficient and volatility elevated; investors should treat the consensus as a directional guide rather than a precise target, and watch for estimate revisions around the next earnings print as the key signal.

Drowning in data?

Find the real signal!

Bulls vs Bears: NVST Investment Factors

The bear case currently has the stronger evidence base: the headline Q3 profit is a one-time artifact, revenue growth is only 3.2% YoY, and FCF of $226.2M is thin relative to the $3.65B market cap, while analyst ratings are genuinely split and Baird just downgraded. The bull case rests on valuation and balance sheet rather than momentum — 1.34x PS is near the bottom of a multi-year band, gross margin is holding at 55-58%, and the stock has 19.62 points of relative strength over the past year. The single most important tension is whether the consensus $3.17B revenue and $1.98 EPS are achievable off a ~$2.88B run-rate; if that ~10% growth step-up materializes, the low multiple re-rates sharply, but if the top line stays flat the stock is fairly valued at best. Until estimate revisions confirm the growth inflection, the risk/reward is balanced rather than compelling.

Bullish

  • Valuation near multi-year floor: At 1.34x PS and 1.17x P/B, NVST trades at the bottom of its own multi-year band (5.5x-6.1x PS in 2022-2023, 8.3x-13.7x in 2022). The stock is priced for stagnation, so even a partial re-rating to 2.0x-2.5x sales on stabilizing earnings would imply meaningful upside.
  • Gross margin holding at 55-58%: Gross margin has been stable at 55.0%-57.9% across the last four quarters (Q3 2026: 57.9%), showing pricing and mix are intact despite soft dental demand. That resilience is the foundation for any operating leverage recovery as SG&A of $284.2M normalizes against a growing top line.
  • Balance sheet provides downside cushion: Debt-to-equity of 0.51, a current ratio of 2.38, and $1.159B of cash at Q3 2026 mean there is no solvency risk in the near term. Interest coverage of roughly 66x on the reported quarter (7.4x normalized) leaves ample room to fund buybacks ($103M repurchased in Q2 2026) and weather a slow demand recovery.
  • Relative strength leadership over 12 months: NVST is up 29.21% over the trailing year versus SPY's 9.59%, a 19.62-point relative advantage, and up 9.24% over the past month against SPY's -4.99% (14.23-point swing). The one-month/three-month divergence (three-month relative strength of -5.68) is characteristic of a correction within an uptrend rather than a trend break.

Bearish

  • Q3 profit is a one-time optical illusion: Q3 2026 net income of $508.3M and EPS of $3.16 were inflated by a large one-time gain, evidenced by other non-cash items of -$402.9M in the cash flow statement. Normalized operating income is closer to $112M (~16% of revenue), consistent with the 8.3% operating margin and 1.7% net margin in the key metrics snapshot.
  • Revenue growth stuck in low single digits: Q3 2026 revenue of $691.5M rose only 3.22% YoY from $669.9M, and the trailing four-quarter run-rate of ~$2.88B shows a flat trajectory. Analyst consensus of $3.17B implies roughly 10% growth off that run-rate, a step-up the company has not demonstrated it can deliver.
  • Free cash flow is lumpy and thin: TTM FCF of $226.2M against a $3.65B market cap is a modest ~6.2% FCF yield, and quarterly FCF has swung from -$15.8M in Q1 2026 to $88.5M in Q2 and $61.8M in Q3. Buyback-funded capital returns are only sustainable if cash generation normalizes, and ROE of just 1.51% reflects the depressed earnings base.
  • Analyst sentiment is mixed and downgrade-prone: Coverage is thin at only 3 analysts, and the ratings feed is split: Evercore ISI and Leerink at Outperform, JP Morgan upgraded to Overweight, but UBS, Piper Sandler, BMO and Needham at Neutral/Hold, and Baird downgraded from Outperform to Neutral in mid-October. With no published consensus price target, price discovery is inefficient and volatility likely stays elevated.

NVST Technical Analysis

Envista is in a choppy but net-positive uptrend: the stock is up 29.21% over the trailing year versus a 9.59% gain for SPY, a relative strength advantage of 19.62 percentage points. The current price of $25.17 sits roughly 89% of the way through its 180-day range, with the period low near $22.40 (early June) and the high at $28.71 (mid-August); that positioning near the upper end of the range signals momentum but also leaves limited headroom before the stock retests overhead supply. The 25.97% max drawdown over the window underscores that this is a volatile, headline-sensitive name rather than a smooth compounder.

Short-term momentum is re-accelerating after a mid-cycle pullback: the stock is up 9.24% over the past month versus a -4.99% decline in SPY, a 14.23-point relative strength swing that marks a sharp reversal from the three-month picture, where NVST is down 10.59% against SPY's -4.91% (relative strength of -5.68). That divergence — strong 1-month, weak 3-month, strong 1-year — is characteristic of a correction within an uptrend rather than a trend break, and the November 4 spike to $27.19 (a single-session jump of roughly 9.8% from $24.77) followed by consolidation at $25.17 suggests the market digested news-driven volatility without giving back the gains. Volume of 3.23M shares on the latest session is unremarkable, so confirmation of the move would require follow-through volume.

Key technical levels are well defined: support sits at the $22.40–$22.65 zone (the June and October lows), with secondary support near $23.00, while resistance is the $28.71 August high, followed by the $28.37 late-July spike. A decisive break above $28.71 would signal a fresh leg higher and likely invite momentum buyers, whereas a close below $22.40 would invalidate the uptrend structure and open the door to the low-$20s. With a beta not provided in the data, position sizing should lean on the observed 25.97% max drawdown and the stock's demonstrated ability to move ~10% in a single session as the practical volatility guide.

Beta

—

—

Max Drawdown

-26.0%

Largest decline past year

52-Week Range

—

Price range past year

Annual Return

+23.1%

Cumulative gain past year

PeriodNVST ReturnS&P 500
1m+7.3%-2.0%
3m-12.8%-2.8%
6m+5.5%+2.1%
1y+23.1%+12.3%
ytd+12.9%+10.6%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

NVST Fundamental Analysis

Revenue is growing but only modestly: Q3 2026 revenue of $691.5M rose 3.22% year over year from $669.9M in Q3 2025, and the trailing four-quarter run-rate of roughly $2.88B (Q4 2025 $750.6M, Q1 2026 $705.5M, Q2 2026 $730.5M, Q3 2026 $691.5M) shows a relatively flat, low-single-digit trajectory rather than acceleration. Segment data show Specialty Products & Technologies at $1.208B and Equipment & Consumables at $679.3M, meaning the higher-margin implant and orthodontics franchise is the larger revenue base and the key swing factor for growth. Analyst consensus revenue of $3.17B implies roughly 10% growth off the current run-rate, a meaningful step-up that the investment case must deliver on; without it, the growth story remains a modest recovery rather than a re-rating catalyst.

Profitability looks dramatically improved on the surface — Q3 2026 net income of $508.3M and a 73.5% net margin — but this is distorted by a one-time gain, as evidenced by operating income of $515.2M against revenue of $691.5M (74.5% operating margin) and other non-cash items of -$402.9M in the cash flow statement. Normalizing for that item, underlying operating income is closer to $112M, or roughly 16% of revenue, consistent with the 8.3% operating margin and 1.7% net margin in the key metrics snapshot. Gross margin has been stable and healthy at 55.0%–57.9% across the last four quarters (Q3 2026: 57.9%, Q2: 55.7%, Q1: 55.3%, Q4 2025: 55.0%), suggesting pricing and mix are holding even as SG&A of $284.2M consumes a large share of gross profit.

The balance sheet is solid: debt-to-equity of 0.51, a current ratio of 2.38, and cash of $1.159B at the end of Q3 2026 provide ample liquidity, while interest coverage of roughly 66x on the reported quarter (and 7.4x on a normalized basis) indicates low financial risk. Free cash flow is the weak spot — TTM FCF of $226.2M against a $3.65B market cap implies a modest FCF yield of about 6.2%, and quarterly FCF has been lumpy (-$15.8M in Q1 2026, $88.5M in Q2, $61.8M in Q3) due to working capital swings. ROE of just 1.51% reflects the depressed earnings base, and with no dividend and a 0% payout ratio, capital returns depend on buybacks ($103M repurchased in Q2 2026 alone), which are only sustainable if cash generation normalizes.

Quarterly Revenue

$691500000.0B

2026-10

Revenue YoY Growth

+3.2%

YoY Comparison

Gross Margin

57.9%

Latest Quarter

Free Cash Flow

$226200000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Equipment and Consumables
Specialty Products and Technologies

Open an Account, get $2 TSLA now!

Valuation Analysis: Is NVST Overvalued?

Because trailing net income is positive but heavily distorted by the one-time Q3 gain, the trailing PE of 77.5x is not a meaningful anchor; the more informative metric is the price-to-sales ratio of 1.34x, which is low in absolute terms for a 55% gross-margin medtech business and reflects the market's skepticism about the earnings base. The forward PE of -0.74x in the provided data is clearly a data artifact (negative PEG of -0.74 likewise), so the cleanest forward signal comes from consensus EPS of $1.98 against the $25.17 price, implying roughly 12.7x forward earnings — a valuation that bakes in modest expectations rather than optimism.

On peer comparison, the data set does not include an explicit industry-average multiple, so a direct spread cannot be quantified; however, the 1.34x PS and 12.2x EV/EBITDA are at the low end of what diversified dental and medtech suppliers typically command, consistent with Envista's below-peer growth (3.2% YoY) and thin normalized margins (8.3% operating). The 1.17x price-to-book is similarly undemanding and suggests the market is valuing the franchise close to its accounting equity, a discount that would only be justified if implant and ortho demand remains structurally soft. If the company delivers the consensus $3.17B revenue and $1.98 EPS, the current multiple would look inexpensive; the risk is that the consensus is too optimistic given the recent flat top line.

Historically, Envista's PS ratio has compressed dramatically: it traded at 5.5x–6.1x in the 2022–2023 period (e.g., 5.46x in Q3 2026 per historical ratios, 6.12x in Q2 2026, and 8.3x–13.7x back in 2022), versus the current 1.34x — near the bottom of its own multi-year band. That compression partly reflects genuine fundamental deterioration (margin pressure, one-time charges, weak ROE), but it also means the stock is priced for little improvement; a return to even 2.0x–2.5x sales on stabilizing earnings would imply meaningful upside, while a further slide toward 1.0x would signal the market expects continued stagnation.

PE

77.5x

Latest Quarter

vs. Historical

High-End

5-Year PE Range 19x~54x

vs. Industry Avg

40.3x

Industry PE ~40.3x*

EV/EBITDA

12.2x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on earnings quality and cash conversion. The Q3 2026 net income of $508.3M and EPS of $3.16 were inflated by a one-time gain, with other non-cash items of -$402.9M in the cash flow statement, so normalized operating income is closer to $112M (~16% of revenue) against an 8.3% reported operating margin and 1.7% net margin. Free cash flow is the weak spot: TTM FCF of $226.2M against a $3.65B market cap is a ~6.2% yield, and quarterly FCF swung from -$15.8M in Q1 2026 to $88.5M in Q2 and $61.8M in Q3 on working capital. Revenue is also concentrated in the higher-margin Specialty Products & Technologies segment at $1.208B, so any implant or ortho softness hits the profit engine directly, and ROE of just 1.51% shows how little the equity base is currently earning.

Market and competitive risks are dominated by valuation compression and demand sensitivity. At 1.34x PS and 12.2x EV/EBITDA, NVST is already at the low end of diversified dental and medtech multiples, but that discount is justified by 3.2% YoY growth and thin normalized margins — if growth stays flat, the multiple can slide further toward 1.0x sales. Peer XRAY's Q2 beat was overshadowed by margin compression and soft dental demand, a direct read-across to NVST's clinician-driven implant and ortho franchise. Analyst sentiment is fragile with only 3 contributors and Baird's mid-October downgrade to Neutral, and the stock's demonstrated ability to move ~10% in a single session (the November 4 spike from $24.77 to $27.19) means headline risk translates into outsized price swings; with beta not provided, the 25.97% max drawdown is the practical volatility guide.

In a worst-case scenario, flat-to-declining dental utilization forces consensus revenue of $3.17B to be cut toward the ~$2.88B run-rate, EPS estimates of $1.98 fall toward the low end of $1.965 or below, and the multiple compresses toward 1.0x sales as the market concludes the franchise is structurally stagnant. That combination would take the stock back to its 52-week low of $22.40 (June 2026) and potentially into the low-$20s, a decline of roughly -11% to -20% from the current $25.17. A more severe outcome — a second consecutive soft quarter plus another analyst downgrade — could retest the 25.97% max drawdown, implying a loss of about -26% from current levels. The downside is cushioned by $1.159B of cash and a 0.51 debt-to-equity ratio, so this is a multiple-and-estimate risk rather than a solvency risk.

FAQ

Ranked by severity: first, earnings quality and cash conversion — Q3 2026 net income of $508.3M was inflated by a one-time gain (other non-cash items of -$402.9M), normalized operating income is closer to $112M, and quarterly free cash flow swung from -$15.8M in Q1 2026 to $88.5M in Q2 and $61.8M in Q3. Second, growth and estimate risk — revenue rose just 3.22% YoY to $691.5M against a $3.17B consensus implying roughly 10% growth off the ~$2.88B run-rate, so a cut toward the run-rate would push EPS below the $1.965 low estimate. Third, demand and competitive risk — peer XRAY's Q2 beat was overshadowed by margin compression and soft dental demand, a direct read-across to the $1.208B Specialty Products & Technologies segment that carries the highest margins. Fourth, sentiment and liquidity risk — only 3 analysts cover the stock, ratings are split, Baird downgraded to Neutral in mid-October, and there is no published consensus price target, so price discovery is inefficient and the stock has shown it can move ~10% in a session (the November 4 jump from $24.77 to $27.19).

The base case carries 55% probability with a $24-$28 range, assuming revenue growth of 3-6% (below the $3.17B consensus), gross margin held at 55-58%, and EPS near $1.98, implying about 12.7x forward earnings. The bull case at 25% probability targets $30-$32 and requires revenue to reach the $3.17B consensus with EPS at or above the $2.017 high, gross margin near 58%, normalized operating margin above 12%, and a re-rating toward 1.6x-1.7x sales that clears the $28.71 August high. The bear case at 20% probability targets $20-$22.40, retesting the June 2026 52-week low, if consensus revenue is cut toward the ~$2.88B run-rate, EPS drifts to $1.965 or below, and the multiple compresses toward 1.0x sales — a path that could approach the 25.97% max drawdown, or roughly -26% from current levels. The base case is most likely because the tightly clustered three-analyst EPS range of $1.965-$2.017 signals conviction on near-term numbers even as the growth step-up remains unproven.

On the metrics that matter, NVST looks modestly undervalued relative to its own history but fairly valued relative to its growth. The trailing PE of 77.5x is meaningless because trailing earnings are distorted by the one-time Q3 gain, and the forward PE of -0.74x and PEG of -0.74 are data artifacts; the cleanest read is 1.34x sales, 1.17x book and 12.2x EV/EBITDA, plus roughly 12.7x the $1.98 consensus EPS at $25.17. That is a steep discount to the 5.5x-6.1x PS the stock commanded in 2022-2023 and the 8.3x-13.7x seen in 2022, but the compression is partly earned given 3.2% growth and an 8.3% normalized operating margin. The market is effectively pricing in permanent stagnation: a return to even 2.0x-2.5x sales on stabilizing earnings would imply meaningful upside, while a slide toward 1.0x would signal expectations of continued decline. Net, the stock is cheap versus its own history and roughly fair versus its fundamentals.

The risk/reward is balanced rather than compelling at $25.17. On the positive side, the stock trades at 1.34x sales, 1.17x book and 12.2x EV/EBITDA — near the bottom of a multi-year band that saw 5.5x-6.1x PS in 2022-2023 — against a 55-58% gross margin and $1.159B of cash with 0.51 debt-to-equity, so downside is cushioned and a modest re-rating would be powerful. On the negative side, revenue grew only 3.22% YoY in Q3 2026, TTM free cash flow of $226.2M is a ~6.2% yield, ROE is 1.51%, and the Q3 EPS of $3.16 was inflated by a one-time gain (other non-cash items of -$402.9M). There is no published consensus price target to anchor upside, coverage is only 3 analysts, and Baird downgraded to Neutral in mid-October. It is a reasonable buy for value-oriented investors with a 12-24 month horizon who can tolerate a retest of the $22.40 low (roughly -11%), but not for anyone needing near-term catalysts or income.

NVST fits a medium-to-long-term holding period of at least 12-24 months rather than short-term trading. The thesis depends on a slow fundamental inflection — revenue accelerating from 3.22% toward the ~10% implied by the $3.17B consensus and normalized operating margin recovering from 8.3% — which will not resolve in a single quarter, and with only 3 analysts and no published price target, near-term price action is headline-driven rather than fundamentally anchored. Volatility is high: the stock has a 25.97% max drawdown over the past 180 days, swung from $22.40 in June to $28.71 in August, and jumped roughly 9.8% in a single session on November 4, so short-term traders face whipsaw risk without an edge. There is no dividend (0% yield, 0% payout), so total return comes entirely from price appreciation and buybacks, and the 29.21% one-year gain versus SPY's 9.59% suggests the initial re-rating is largely done. A patient value investor with a 12-24 month horizon and tolerance for a possible retest of $22.40 is the natural holder.